The U.S. Food and Drug Administration this week approved Xeljanz (tofacitinib) for the treatment of moderate to severe rheumatoid arthritis (RA) in adults who have not responded to methotrexate. The twice-daily pill works by blocking molecules known as “Janus kinases.” …

Loch Ness Monster Arthritis isn’t some sort of bizarre disease that you’re likely to learn about while watching reruns of terrible sitcoms in the wee hours of the morning. No, according to a team of researchers at the University of …